MIRA
MIRA PHARMACEUTICALS, INC.
$0.9400
-2.08%
$39.5M
No data for this timeframe.
Vol
Market Cap$39.5M
Cap SizeNano Cap
Inst. Holders11 funds
Inst. Value$1.2M
Inst. Activity2 buys / 1 sells
SEC Reports4
Recent Activity
Jun 8, 2026
SEC
Mira Pharmaceuticals disclosed the departure of CFO Alan Weichselbaum (effective June 6, 2026) and the appointment of An
8-K — Impact 3/10
Jun 4, 2026
SEC
MIRA Pharmaceuticals entered into an Amended and Restated Exclusive License Agreement with MIRALOGX LLC, securing worldw
8-K — Impact 3/10
May 27, 2026
SEC
MIRA Pharmaceuticals expanded its exclusive license for Ketamir-2 from North America to worldwide rights and added inter
8-K — Impact 5/10
May 12, 2026
earnings_calendar
MIRA Q1 2026 Earnings Scheduled — 2026-05-12
Mar 30, 2026
Insider
Aminov Erez was granted 83,500 shares
Chief Executive Officer
Inst.
VANGUARD GROUP INC — DOUBLED
660,497 shares ($997.4K)
Inst.
TWO SIGMA INVESTMENTS, LP — TRIM
27,044 shares ($40.8K)
Analyst Ratings
2Strong Buy
4Buy
1Hold
0Sell
0Strong Sell
Historical Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Sep 30, 2024 | Rodman & Renshaw | INITIATE | Buy |
| Aug 5, 2024 | Ascendiant Capital | INITIATE | Buy |
Latest Reports
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| VANGUARD CAPITAL MANAGEMENT LLC | $742.5K | — |
| VANGUARD FIDUCIARY TRUST CO | $181.3K | — |
| BlackRock, Inc. | $120.2K | — |
| STATE STREET CORP | $52.5K | — |
| COMMONWEALTH EQUITY SERVICES, LLC | $37.5K | ADD |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| Mar 30, 2026 | Aminov Erez | A | $0.00 |
11 institutional holders with $1.2M total value (1,150,109 shares) as of 2026-Q1. Top holders: VANGUARD, VANGUARD, BlackRock,.
Top Institutional Holders — 2026-Q1
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | VANGUARD CAPITAL MANAGEMENT LLC | 693,912 | $742.5K | 60.3% | — |
| 2 | VANGUARD FIDUCIARY TRUST CO | 169,483 | $181.3K | 14.7% | — |
| 3 | BlackRock, Inc. | 112,346 | $120.2K | 9.8% | — |
| 4 | STATE STREET CORP | 49,100 | $52.5K | 4.3% | — |
| 5 | COMMONWEALTH EQUITY SERVICES, LLC | 35,067 | $37.5K | 3.0% | ADD +69.5% |
| 6 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 25,146 | $26.9K | 2.2% | — |
| 7 | Vanguard Global Advisers, LLC | 24,306 | $26.0K | 2.1% | — |
| 8 | FIFTH THIRD BANCORP | 20,000 | $21.4K | 1.7% | — |
| 9 | Mariner, LLC | 16,500 | $17.7K | 1.4% | ADD +43.5% |
| 10 | CITIGROUP INC | 4,226 | $4.5K | 0.4% | — |
| 11 | WELLS FARGO & COMPANY/MN | 23 | $25.00 | 0.0% | — |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| VANGUARD GROUP INC | DOUBLED | 203,643 | 660,497 | +224.3% | $997.4K | 2025-Q4 |
| TWO SIGMA INVESTMENTS, LP | TRIM | 45,703 | 27,044 | -40.8% | $40.8K | 2025-Q4 |
| BANK OF AMERICA CORP /DE/ | ADD | 140 | 261 | +86.4% | $395.00 | 2025-Q4 |
| VANGUARD GROUP INC | ADD | 117,824 | 203,643 | +72.8% | $277.0K | 2025-Q3 |
| TWO SIGMA INVESTMENTS, LP | DOUBLED | 19,887 | 45,703 | +129.8% | $62.2K | 2025-Q3 |
| UBS Group AG | TRIM | 500 | 216 | -56.8% | $294.00 | 2025-Q3 |
| Mariner, LLC | ADD | 11,500 | 16,500 | +43.5% | $20.0K | 2025-Q2 |
| COMMONWEALTH EQUITY SERVICES, LLC | ADD | 15,072 | 25,547 | +69.5% | $25.00 | 2025-Q1 |
| BANK OF AMERICA CORP /DE/ | DOUBLED | 88 | 10,099 | +11376.1% | $11.5K | 2024-Q4 |
1 unique insiders with 1 transactions. Net insider value: $0.00 ($0.00 bought, $0.00 sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Mar 30, 2026 | Aminov Erez | Chief Executive Officer | AWARD | 83,500 | — | — |
4 SEC filing reports analyzed. Sentiment: 1 bullish, 0 bearish, 0 mixed, 3 neutral. Avg impact: 3.5/10.
NEUTRAL
8-K
3/10
Mira Pharmaceuticals disclosed the departure of CFO Alan Weichselbaum (effective June 6, 2026) and t
Jun 8, 2026
NEUTRAL
8-K
3/10
MIRA Pharmaceuticals entered into an Amended and Restated Exclusive License Agreement with MIRALOGX
Jun 4, 2026
BULLISH
8-K
5/10
MIRA Pharmaceuticals expanded its exclusive license for Ketamir-2 from North America to worldwide ri
May 27, 2026
NEUTRAL
8-K
3/10
MIRA Pharmaceuticals announced the publication of a peer-reviewed manuscript on its preclinical drug
May 13, 2026
No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.
Historical analyst distribution (last covering-analyst action Sep 2024): 86% buy across 7 analysts — 2 strong buy, 4 buy, 1 hold, 0 sell, 0 strong sell. No current recommendation available.
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q | $0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
| Next Q 2026-03-31 |
$0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
| Current FY 2025-12-31 |
$0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
| Next FY | $0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
2 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 2 initiations.
Historical Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Sep 30, 2024 | Rodman & Renshaw | INITIATE | — | Buy |
| Aug 5, 2024 | Ascendiant Capital | INITIATE | — | Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| May 1, 2026 | 2 | 4 | 1 | 0 | 0 | 86% | |
| Apr 1, 2026 | 2 | 4 | 1 | 0 | 0 | 86% | |
| Mar 1, 2026 | 2 | 4 | 1 | 0 | 0 | 86% | |
| Feb 1, 2026 | 2 | 4 | 1 | 0 | 0 | 86% | |
| Jan 1, 2026 | 2 | 4 | 1 | 0 | 0 | 86% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
May 12, 2026
earnings_calendar
MIRA Q1 2026 Earnings Scheduled — 2026-05-12
Apr 1, 2026
short_volume
Short Volume: MIRA — 58.2% short (0.3M / 0.5M)
Short: 305,323 | Exempt: 9,600 | TRF Vol: 524,621 | Short Ratio: 58.2% | Off-exchange volume (dark pool + OTC)